Trial Details

Not Recruiting
Basic Information
Clinical ID c5516
Identifier ACTRN12606000240549
Trial Title Phase Ib Chronic Pharmacokinetic and Tolerability Study of Oral NV-52 in Normal Healthy Volunteers
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Healthy Volunteers; Healthy Volunteers;Other - Research that is not of generic health relevance and not applicable to specific health categories listed above
Interventions NV-52 is an experimental drug which is being developed as an orally-delivered non-toxic agent being developed for the maintenance of remission in inflammatory bowel disease (IBD). The duration of intervention is 10 days at a dose of 400 mg per day with n
Participant Information
Sponsor Novogen Research Pty Limited
City NULL
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT
Study Design
Study Type Interventional
Phase PHASE1
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL